NCT06757517View on ClinicalTrials.gov

Effects of Intranasal Oxytocin in the Treatment of Benzodiazepine Withdrawal: A Pilot RCT

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Benzodiazepine Dependence
Interventions
DRUG

Oxytocin nasal spray

Syntocinon contains synthetic oxytocinfor intranasal use, 6.7 microg (4 IU) per dose. We are planning to use 4 insufflations (16 IU) three times daily (i.e. a total daily dose of 48 IU).

DRUG

Saline (NaCl 0,9 %) (placebo)

Saline intranasal placebo comparator

Trial Locations (1)

7091

RECRUITING

Blue Cross, Clinic Lade, Trondheim

All Listed Sponsors
collaborator

Norwegian University of Science and Technology

OTHER

collaborator

Lade Behandlingssenter, Blå Kors

UNKNOWN

lead

St. Olavs Hospital

OTHER